Skip to main content
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. — Investor Relations & Filings

Ticker · GLUE ISIN · US61225M1027 US Manufacturing
Open in API
Filings indexed 324 across all filing types
Latest filing 2024-05-14 Major Shareholding Noti…
Country US United States of America
Listing US GLUE

About Monte Rosa Therapeutics, Inc.

https://www.monterosatx.com/

Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops small molecule precision medicines known as molecular glue degraders (MGDs). The company's proprietary drug discovery platform is engineered to rationally design MGDs that leverage the body's natural protein disposal system to selectively eliminate disease-causing proteins. This approach targets proteins that have been historically considered "undruggable" or are inadequately addressed by existing therapies. By integrating expertise in chemistry, artificial intelligence, structural biology, and proteomics, Monte Rosa is advancing a pipeline of therapeutic candidates primarily for cancer and other serious diseases.

Recent filings

Filing Released Lang Actions
NEW ENTERPRISE ASSOCIATES 17, L.P. -- MONTE ROSA THERAPEUTICS 13D/A(#1)
Major Shareholding Notification
2024-05-14 English
10-Q
Interim / Quarterly Report Q1 2024
2024-05-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 9, 2024, by Monte Rosa Therapeutics, Inc. It announces the company's financial results for the quarter ended March 31, 2024, and includes a press release and a corporate presentation as exhibits. The text explicitly states that the press release is furnished as an exhibit and the corporate presentation is also furnished as an exhibit. The document itself is relatively short (3995 characters) and serves as an announcement of the earnings release and investor presentation rather than containing the full financial results or detailed analysis. According to the 'Menu vs Meal' rule, this is an announcement of reports, not the reports themselves. Therefore, the appropriate classification is Earnings Release (ER) for the financial results announcement and Investor Presentation (IP) for the corporate presentation. However, since the document is a Form 8-K announcing both, and the main content is the earnings announcement, the best fit is Earnings Release (ER).
2024-05-09 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated April 29, 2024, by Monte Rosa Therapeutics, Inc. The key content is the resignation of the Chief Scientific Officer and related management changes. This corresponds to announcements about changes in the company's board of directors or senior management. There are no financial statements or detailed financial data, so it is not an annual or interim report. The document is not a press release or earnings release but a regulatory filing specifically about management changes. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 4241 characters, which is consistent with a typical 8-K filing for management changes.
2024-05-02 English
Regulatory Filings 2024
Regulatory Filings
2024-05-01 English
ARS
Annual Report
2024-04-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.